Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
Advertisement

Related Content

WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
US-India Healthcare Summit: New Business Models Needed To Reach the World's Poor
WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
Sanofi Aventis Maps Out India R&D Strategy To Broaden Reach Into Untapped Markets
M&A In India May Lose Steam As Potential Sellers Raise Prices, Investment Bankers Say
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Sanofi Pasteur's India Arm Shantha Biotech Bags WHO Supply Contract For Pentavalent Vaccines
Sanofi Pasteur's India Arm Shantha Lands WHO Supply Contract For Pentavalent Vaccines
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
Advertisement
UsernamePublicRestriction

Register

SC072612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel